June 2026 Catalyst Events
- 2026-06-01: Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO) — Intellia Therapeutics Inc. — Submission
- 2026-06-01: Bel-sar (AU-011) - (CoMpass) — Aura Biosciences Inc. — Topline Data
- 2026-06-01: Ivonescimab with platinum-based chemotherapy compared with tislelizumab - (AK112-306/HARMONi-6) — Summit Therapeutics Inc. — Phase 3
- 2026-06-01: Atebimetinib (IMM-1-104) + mGnP — Immuneering Corporation — Phase 2a
- 2026-06-01: Obefazimod - (ABTECT) — Abivax SA — Submission
- 2026-06-01: Volixibat - (VISTAS) — Mirum Pharmaceuticals Inc. — Submission
- 2026-06-01: ALXN1840 (tiomolibdate choline) - (ALXN1840-WD-204) — Monopar Therapeutics Inc. — Phase 2
- 2026-06-01: Brenetafusp (IMC-F106C) - (PRAME-A02) — Immunocore Holdings plc — Phase 1/2
- 2026-06-01: Pluvicto (lutetium (177Lu) vipivotide tetraxetan) - (PSMAddition) — Novartis AG — Submission
- 2026-06-01: GP2 (GLSI-100) - (FLAMINGO-01) — Greenwich LifeSciences Inc. — Phase 3
- 2026-06-01: Allocetra - (ENX-CL-05-001) — Enlivex Ltd. — Phase 2a
- 2026-06-01: Olverembatinib (HQP1351) with blinatumomab — Ascentage Pharma Group International — Phase 1
- 2026-06-01: RP2 with nivolumab (nivo) — Replimune Group Inc. — Phase 1
- 2026-06-01: VYD2311 - (DECLARATION) — Invivyd Inc. — Phase 3
- 2026-06-01: Ivonescimab with Oxaliplatin + Fluorouracil + Leucovorin Calcium — Summit Therapeutics Inc. — Phase 2
- 2026-06-01: IMA203CD8 - (GEN2) — Immatics N.V. — Conference Presentation
- 2026-06-01: Darovasertib with crizotinib - (OptimUM-02) — IDEAYA Biosciences Inc. — Phase 2/3
- 2026-06-01: BHV-8100 — Biohaven Ltd. — Phase 1
- 2026-06-01: ERLEADA (apalutamide) - (PROTEUS) — Johnson & Johnson — Phase 3
- 2026-06-01: IMFINZI (Durvalumab) + TACE - (EMERALD-3) — AstraZeneca PLC — Phase 3
- 2026-06-01: Elraglusib (9-ING-41) - (ACTUATE-1801) — Actuate Therapeutics Inc. — Phase 2
- 2026-06-01: Brelovitug - (AZURE) — Mirum Pharmaceuticals Inc. — Submission
- 2026-06-01: Iopofosine (CLR 131) - (CLOVER-WaM) — Cellectar Biosciences Inc. — Phase 2b
- 2026-06-01: Alrizomadlin (APG-115) with lisaftoclax (APG-2575) — Ascentage Pharma Group International — Phase 1
- 2026-06-01: RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3) — Replimune Group Inc. — Phase 3
- 2026-06-01: FT836 — Fate Therapeutics Inc. — Phase 1
- 2026-06-01: RETEVMO (Selpercatinib) - (LIBRETTO-432) — Eli Lilly and Company — Phase 3
- 2026-06-01: Anzu-cel (anzutresgene autoleucel, IMA203) (ACTengine) - (SUPRAME) — Immatics N.V. — Phase 1b
- 2026-06-01: MONJUVI (tafasitamab) - (frontMIND) — Incyte Corporation — Phase 3
- 2026-06-01: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab - (KEYNOTE-942) — Moderna Inc. — Phase 2b
- 2026-06-01: LB2102 — Legend Biotech Corporation — Phase 1
- 2026-06-01: Pociredir (FTX-6058) - (PIONEER) — Fulcrum Therapeutics Inc. — Phase 1b
- 2026-06-01: LYTENAVA (bevacizumab-vikg) / ONS-5010 - (NORSE EIGHT) — Outlook Therapeutics Inc. — Submission
- 2026-06-01: APR-1051 - (ACESOT-1051) — Aprea Therapeutics Inc. — Conference Presentation
- 2026-06-01: AL102 - (RINGSIDE) — Immunome Inc. — Phase 3
- 2026-06-01: Lorundrostat - (Launch-HTN) — Mineralys Therapeutics Inc. — Phase 3
- 2026-06-01: INB-200 — IN8bio Inc. — Phase 1
- 2026-06-01: VY1706 — Voyager Therapeutics Inc. — IND-Enabling
- 2026-06-01: PRAX-628 - (POWER1) — Praxis Precision Medicines Inc. — Phase 2/3
- 2026-06-01: Camzyos (mavacamten) - (SCOUT-HCM) — Bristol-Myers Squibb Company — Regulatory Decision
- 2026-06-01: Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC) — AIM ImmunoTech Inc. — Phase 2
- 2026-06-01: INB-400 — IN8bio Inc. — Phase 2
- 2026-06-01: NUBEQA (darolutamide) - (ARACOG) — Bayer AG ADR — Phase 2
- 2026-06-02: LB2501 — Legend Biotech Corporation — Phase 1
- 2026-06-02: TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) - (ProstACT) — Telix Pharmaceuticals Limited — Phase 3
- 2026-06-02: Namodenoson - (CF102-222PC) — Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) — Phase 2a
- 2026-06-02: XPRO1595 - (MINDFuL) — INmune Bio Inc. — Phase 2
- 2026-06-02: OST-HER2 (AOST-2121) — OS Therapies Incorporated — Phase 3
- 2026-06-02: CAN-2409 (aglatimagene besadenovec) plus valacyclovir (prodrug) — Candel Therapeutics Inc. — Submission
- 2026-06-02: DISC-0974 - (RALLY-MF) — Disc Medicine Inc. — Phase 2
- 2026-06-02: VAX-A1 — Vaxcyte Inc. — Topline Data
- 2026-06-02: PAS-004 — Pasithea Therapeutics Corp. — Phase 1
- 2026-06-02: Selinexor (XPORT-MF-034) - (SENTRY) — Karyopharm Therapeutics Inc. — Phase 3
- 2026-06-02: CTx-1301 (fixed dose, pediatric study) — Cingulate Inc. — CRL
- 2026-06-02: Ifetroban — Cumberland Pharmaceuticals Inc. — Phase 2a
- 2026-06-02: Gedatolisib with Fulvestrant - (VIKTORIA-1) — Celcuity Inc. — Regulatory Decision
- 2026-06-02: Izalontamab brengitecan vs chemotherapy - (PANKU-Esophagus01) — Bristol-Myers Squibb Company — Phase 3
- 2026-06-02: QRX003 — Quoin Pharmaceuticals Ltd. — Initial Data
- 2026-06-02: Lucid-21-302 - (Lucid-MS) — Quantum Biopharma Ltd. — Submission
- 2026-06-02: FID-007 with cetuximab — Fulgent Genetics Inc. — Phase 2
- 2026-06-02: KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01) — BeyondSpring Inc. — Phase 2
- 2026-06-02: ENTR-601-45 - (ELEVATE-45-201) — Entrada Therapeutics Inc. — Phase 1/2
- 2026-06-02: Giredestrant - (lidERA) — Roche Holding AG ADR — Regulatory Decision
- 2026-06-02: IBIO-600 — iBio Inc. — Phase 1
- 2026-06-02: LP-300 - (Harmonic) — Lantern Pharma Inc. — Phase 2
- 2026-06-02: Ersodetug (RZ358) - (upLIFT) — Rezolute Inc. — Topline Data
- 2026-06-02: BMC128 with Opdivo — Bristol-Myers Squibb Company — Phase 1
- 2026-06-02: Camizestrant - (SERENA-6) — AstraZeneca PLC — Regulatory Decision
- 2026-06-02: Onvansertib + bevacizumab - (CRDF-004) — Cardiff Oncology Inc. — Phase 2
- 2026-06-02: Izalontamab brengitecan - (PANKU-Breast02) — Bristol-Myers Squibb Company — Phase 3
- 2026-06-03: Actinium-225 (Ac-225) - (ATNM-400) — Actinium Pharmaceuticals Inc. — Preclinical
- 2026-06-03: Nintedanib Dpi (Mnkd-201) - (INFLO-1) — MannKind Corporation — Initial Data
- 2026-06-03: VS-7375 - (TARGET-D 101) — Verastem Inc. — Phase 1
- 2026-06-03: Efgartigimod - (ALKIVIA) — argenx SE — Conference Presentation
- 2026-06-03: TTX-MC138 - (PRE-I-SPY) — TransCode Therapeutics Inc. — Phase 1a
- 2026-06-03: CYWC628 — FibroBiologics Inc. — Phase 1/2
- 2026-06-03: Cosentyx - (REPLENISH) — Novartis AG — Conference Presentation
- 2026-06-03: Resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) - (RESET-SSc) — Cabaletta Bio Inc. — Conference Presentation
- 2026-06-03: Darlifarnib (KO-2806) and adagrasib in combination with cabozantinib - (FIT-001) — Bristol-Myers Squibb Company — Phase 1a
- 2026-06-03: Nipocalimab - (JASMINE) — Johnson & Johnson — Phase 2b
- 2026-06-03: Obexelimab - (INDIGO) — Bristol-Myers Squibb Company — Phase 3
- 2026-06-03: KYV-101 - (COMPARE) — Kyverna Therapeutics Inc. — Phase 1/2
- 2026-06-03: QTORIN rapamycin - (SELVA) — Palvella Therapeutics Inc. — Submission
- 2026-06-03: Nipocalimab - (DAHLIAS) — Johnson & Johnson — Phase 2
- 2026-06-03: ZYNLONTA (Loncastuximab Tesirine) and RITUXAN (rituximab) - (LOTIS-5) — ADC Therapeutics SA — Submission
- 2026-06-03: TN-201 - (MyPeak-1) — Tenaya Therapeutics Inc. — Interim Data
- 2026-06-03: SPY072 - (SKYWAY-RD, basket study) — Spyre Therapeutics Inc. — Topline Data
- 2026-06-03: DYNE-101 - (ACHIEVE) — Dyne Therapeutics Inc. — Phase 1/2
- 2026-06-04: ABP-450 (prabotulinumtoxinA) - (BOTOX biosimilar) — AEON Biopharma Inc. Class A — Biosimilar
- 2026-06-04: GH1001 (GH001-PPD-203) — GH Research PLC — Phase 2a
- 2026-06-04: CL-741 — Kairos Pharma Ltd. — Phase 1
- 2026-06-04: Vanrafia (atrasentan) - (ALIGN) — Novartis AG — Phase 3
- 2026-06-04: Romidepsin injection solution, 27.5 mg/5.5 mL — Amneal Pharmaceuticals Inc. — Approved
- 2026-06-04: AN2-502998 — AN2 Therapeutics Inc. — Phase 1
- 2026-06-04: FT819 — Fate Therapeutics Inc. — Initial Data
- 2026-06-04: IMP761 — Immutep Limited — Conference Presentation
- 2026-06-04: brelgometon (ATH-1105) — LeonaBio Inc Com (New) — Phase 1
- 2026-06-04: Dapirolizumab pegol (anti-CD40L) - (PHOENYCS GO) — Biogen Inc. — Phase 3
- 2026-06-04: AVT05 (biosimilar to Simponi Aria/golimumab) — Alvotech — Submission
- 2026-06-04: AVT06 - (EYLEA biosimilar) — Alvotech — Submission
- 2026-06-04: FT839 — Fate Therapeutics Inc. — Initial Data
- 2026-06-05: BG-C9074 — BeOne Medicines Ltd. — Phase 1
- 2026-06-05: Paridiprubart - (EB05) — Edesa Biotech Inc. — Phase 3
- 2026-06-05: KERENDIA (finerenone) - (FIND-CKD) — Bayer AG ADR — Phase 3
- 2026-06-05: CLYM116 — Climb Bio Inc. — Initial Data
- 2026-06-05: Icovamenib (BMF-219) - (COVALENT-112) — Biomea Fusion Inc. — Initial Data
- 2026-06-05: CREXONT (carbidopa and levodopa) - (ELEVATE-PD) — Amneal Pharmaceuticals Inc. — Phase 3
- 2026-06-05: Aleniglipron (GSBR-1290) - (ACCESS and ACCESS II ) — Structure Therapeutics Inc. — Phase 2b
- 2026-06-05: Icovamenib (BMF-219) - (COVALENT-111) — Biomea Fusion Inc. — Initial Data
- 2026-06-07: ACCG-2671 — Structure Therapeutics Inc. — Phase 1
- 2026-06-08: Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC) — AIM ImmunoTech Inc. — Interim Data
- 2026-06-08: BMF-650 (GLP-131) — Biomea Fusion Inc. — Initial Data
- 2026-06-08: CLN-978 - (OUTRACE RA) — Cullinan Therapeutics Inc. — Phase 1
- 2026-06-08: Korlym - (CATALYST) — Corcept Therapeutics Incorporated — Phase 1
- 2026-06-08: Islatravir (MK-8591D) and Lenacapavir - (ISLEND) — Gilead Sciences Inc. — Phase 3
- 2026-06-08: SL-325 — Shattuck Labs Inc. — Submission
- 2026-06-08: MIPLYFFA (MY-PLY-FAH) (arimoclomol) — Ligand Pharmaceuticals Incorporated — Approved
- 2026-06-08: vopimetostat (TNG462) in combination with RAS(ON) inhibitors (RMC-9805) — Revolution Medicines Inc - Ordinary Shares — Initial Data
- 2026-06-08: HYMPAVZI (marstacimab) — Pfizer Inc. — Approved
- 2026-06-08: NGN-401 - (Embolden) — Neurogene Inc. — Topline Data
- 2026-06-08: Tegoprubart - (IIT) — Eledon Pharmaceuticals Inc. — Phase 1b
- 2026-06-08: Trodelvy (sacituzumab govitecan-hziy) + KEYTRUDA (pembrolizumab) - (EVOKE-03) — Gilead Sciences Inc. — Phase 3
- 2026-06-08: AVT16 - (Entyvio biosimilar) — Alvotech — Regulatory Decision
- 2026-06-08: OST-HER2 (AOST-2121) — OS Therapies Incorporated — Submission
- 2026-06-08: COYA 302 - (ALSTARS) — Coya Therapeutics Inc. — Phase 2
- 2026-06-09: BRIUMVI (ublituximab-xiiy) — TG Therapeutics Inc. — Phase 2
- 2026-06-09: ATH434-201 — Alterity Therapeutics Limited — Phase 2
- 2026-06-09: Licaminlimab (OCS-02) - (PREDICT-1) — Oculis Holding AG — Phase 3
- 2026-06-09: UCART22 - (BALLI-01) — Cellectis S.A. — Phase 1
- 2026-06-09: Opaganib (ABC294640) — Redhill Biopharma Ltd. — Phase 2
- 2026-06-09: Bitopertin - (APOLLO) — Disc Medicine Inc. — End of Phase Meeting
- 2026-06-09: EBGLYSS (lebrikizumab-lbkz) - (ADjoin) — Eli Lilly and Company — Approved
- 2026-06-09: Elraglusib - (BEACON2) — Actuate Therapeutics Inc. — Phase 2
- 2026-06-09: ENTYVIO (vedolizumab) - (KEPLER) — Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) — Regulatory Decision
- 2026-06-09: KT-485 (SAR447971) — Kymera Therapeutics Inc. — Phase 1
- 2026-06-10: Trappsol Cyclo - (TransportNPC) — Cyclo Therapeutics Inc. — End of Phase Meeting
- 2026-06-10: TX45 - (APEX) — Tectonic Therapeutic Inc. — Topline Data
- 2026-06-10: Ateganosine (THIO-101) — MAIA Biotechnology Inc. — Phase 2
- 2026-06-11: CB-011 - (CaMMouflage) — Caribou Biosciences Inc. — Initial Data
- 2026-06-11: leronlimab - (SALIENT-AD) — Cytodyn Inc — Phase 2a
- 2026-06-11: VCN-01 — Theriva Biologics, Inc. — Phase 1
- 2026-06-11: Delpacibart braxlosiran (del-brax) - (FORTITUDE) — Novartis AG — Phase 1/2
- 2026-06-11: EVX-04 — Evaxion A/S — Preclinical
- 2026-06-11: Teverelix - (PRECISION-E2) — Medicus Pharma Ltd. — Phase 2
- 2026-06-11: Roxadustat - (MATTERHORN) — AstraZeneca PLC — Phase 3
- 2026-06-11: Revumenib with venetoclax and decitabine/cedazuridine - (SAVE) — Syndax Pharmaceuticals Inc. — Phase 1/2
- 2026-06-11: IM1240 - (CAPTN-3) — Purple Biotech Ltd. — Preclinical
- 2026-06-11: Divesiran (SLN124) - (SANRECO) — Silence Therapeutics Plc — Topline Data
- 2026-06-11: CB-010 - (ANTLER) — Caribou Biosciences Inc. — Conference Presentation
- 2026-06-11: Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007) — Kura Oncology Inc. — Phase 1
- 2026-06-11: Budoprutug (TNT119) — Climb Bio Inc. — Conference Presentation
- 2026-06-11: ELVN-001 - (ENABLE-2) — Enliven Therapeutics Inc. — Phase 3
- 2026-06-11: Atebimetinib (IMM-1-104) + mGnP — Immuneering Corporation — Phase 3
- 2026-06-11: EPCORE (Epcoritamab) - (EPCORE NHL-2) — Genmab A/S — Phase 3
- 2026-06-11: Cemsidomide (CFT7455) - (MOMENTUM) — C4 Therapeutics Inc. — Phase 1b
- 2026-06-12: Navenibart - (ALPHA-STAR) — Astria Therapeutics Inc. — Phase 1/2
- 2026-06-12: Tacabrutideg (BGB-16673-101) - (CaDAnCe-101) — BeiGene Ltd. — Phase 1
- 2026-06-12: Canvuparatide (MBX 2109) - (Avail) — MBX Biosciences Inc. — Phase 2
- 2026-06-12: Sovleplenib - (ESLIM-02) — HUTCHMED (China) Limited — Phase 3
- 2026-06-12: JAK2 V617F mutant-selective inhibitor — Cogent Biosciences Inc. — Submission
- 2026-06-12: Bitopertin - (HELIOS) — Disc Medicine Inc. — Phase 2
- 2026-06-12: KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) — Merck & Company Inc. — Approved
- 2026-06-12: KT-621 - (BREADTH) — Kymera Therapeutics Inc. — End of Phase Meeting
- 2026-06-12: Tivoxavir Marboxil — Traws Pharma Inc. — Phase 1
- 2026-06-12: ZEPZELCA (lurbinectedin) - (LAGOON) — Jazz Pharmaceuticals plc — Phase 3
- 2026-06-12: DISC-0974 - (RALLY-MF) — Disc Medicine Inc. — Phase 2
- 2026-06-12: Bezuclastinib - (APEX) — Cogent Biosciences Inc. — Phase 2
- 2026-06-12: Remibrutinib - (RemIND) — Novartis AG — Phase 3
- 2026-06-13: UCART20x22 - (NatHaLi-01) — Cellectis S.A. — Interim Data
- 2026-06-13: UCART22 - (BALLI-01) — Cellectis S.A. — Interim Data
- 2026-06-13: Setmelanotide — Rhythm Pharmaceuticals Inc. — Phase 2
- 2026-06-13: Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO) — Intellia Therapeutics Inc. — Phase 3
- 2026-06-13: MONJUVI (tafasitamab) - (frontMIND) — Incyte Corporation — Phase 3
- 2026-06-14: verekitug - (VIBRANT) — Upstream Bio Inc. — Phase 2
- 2026-06-14: Olverembatinib (HQP1351) and Lisaftoclax (APG-2575) — Ascentage Pharma Group International — Phase 1b
- 2026-06-14: Paltusotine - (PATHFNDR-1) — Crinetics Pharmaceuticals Inc. — Phase 3
- 2026-06-14: CDX-622 — Celldex Therapeutics Inc. — Phase 1
- 2026-06-15: AJ1-11095 — Eli Lilly and Company — Conference Presentation
- 2026-06-15: Bivamelagon - (SIGNAL) — Rhythm Pharmaceuticals Inc. — Phase 2
- 2026-06-15: EPCORE (Epcoritamab) - (EPCORE NHL-2) — Genmab A/S — Phase 1/2
- 2026-06-15: Mitapivat (AG-348) - (RISE UP) — Agios Pharmaceuticals Inc. — Phase 3
- 2026-06-15: ELI-002 - (AMPLIFY-7P) — Elicio Therapeutics Inc. — Phase 2
- 2026-06-15: Lisaftoclax - (GLORA) — Ascentage Pharma Group International — Phase 2
- 2026-06-15: ZWI-ZW191-101 — Zymeworks Inc. — Phase 1
- 2026-06-15: Navacaprant (NMRA-140) - (KOASTAL-1) — Neumora Therapeutics Inc. — Phase 3
- 2026-06-15: Epcoritamab (Epcor) - (EPCORE DLBCL-1) — Genmab A/S — Phase 3
- 2026-06-15: Oveporexton (TAK-861-2001) — Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) — Regulatory Decision
- 2026-06-15: Olverembatinib (HQP1351) - (POLARIS-2) — Ascentage Pharma Group International — Phase 3
- 2026-06-15: PHVS416 - (RAPIDe-3) — Pharvaris N.V. — Phase 3
- 2026-06-15: AMBELVIST (gadoquatrane) — Bayer AG ADR — Approved
- 2026-06-15: OPK8801001 — Opko Health Inc. — Preclinical
- 2026-06-15: Jaypirca (pirtobrutinib) - (BRUIN CLL-322) — Eli Lilly and Company — Phase 3
- 2026-06-15: Zilurgisertib (INCB000928) - (PROGRESS) — Mirum Pharmaceuticals Inc. — Regulatory Decision
- 2026-06-15: SPY001, SPY002, SPY003 - (SKYLINE) — Spyre Therapeutics Inc. — Topline Data
- 2026-06-15: Lorundrostat - (Launch-HTN) — Mineralys Therapeutics Inc. — Regulatory Decision
- 2026-06-15: INCA033989 — Incyte Corporation — Phase 1
- 2026-06-15: ALTO-207 (CTC-501) — Alto Neuroscience Inc. — Phase 2a
- 2026-06-15: SkinJect (D-MNA/Doxorubicin) - (SKNJCT-005) — Medicus Pharma Ltd. — Phase 2
- 2026-06-15: LX2006 - (SUNRISE-FA) — Lexeo Therapeutics, Inc. — Phase 3
- 2026-06-15: Crinecerfont - (CAHtalyst Pediatric Study) — Neurocrine Biosciences Inc. — Phase 3
- 2026-06-15: TALVEY (talquetamab-tgvs) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) - (MonumenTAL-3) — Johnson & Johnson — Phase 3
- 2026-06-15: ozekibart (INBRX-109) in combination with FOLFIRI - (ChonDRAgon) — Inhibrx Biosciences Inc. — Regulatory Decision
- 2026-06-15: Barzolvolimab (CDX-0159) - (EMBARQ-CSU2) — Celldex Therapeutics Inc. — Submission
- 2026-06-15: Ultomiris (ravulizumab) - (I CAN) — AstraZeneca PLC — Regulatory Decision
- 2026-06-15: Seralutinib (GB002) - (TORREY/PROSERA) — Gossamer Bio Inc. — End of Phase Meeting
- 2026-06-16: HCW9302 — HCW Biologics Inc. — Phase 1
- 2026-06-16: BGE-102 — BioAge Labs Inc. — Topline Data
- 2026-06-16: CMND-100 — Clearmind Medicine Inc. — Phase 1/2
- 2026-06-16: vilamakitug - (V-SPINE (PT064)) — XBiotech Inc. — IND-Enabling
- 2026-06-16: EDG-7500 - (CIRRUS-HCM) — Edgewise Therapeutics Inc. — Phase 2
- 2026-06-16: EB618 — Entera Bio Ltd. — Preclinical
- 2026-06-16: JUVÉDERM - (SKINVIVE) (injectable HA) — AbbVie Inc. — Approved
- 2026-06-16: Givastomig (CLDN18.2 x 4-1BB bispecific antibody) — NovaBridge Biosciences — Conference Presentation
- 2026-06-16: EB613 — Entera Bio Ltd. — Phase 2
- 2026-06-16: CLD-401 — Calidi Biotherapeutics Inc. — IND-Enabling
- 2026-06-16: DM199 (rinvecalinase alfa) — DiaMedica Therapeutics Inc. — Phase 2
- 2026-06-16: PTH(1-34) Peptide Tablets (EB612) — Entera Bio Ltd. — Preclinical
- 2026-06-16: VYD2311 - (LIBERTY) — Invivyd Inc. — Topline Data
- 2026-06-16: LYTENAVA (bevacizumab-vikg) / ONS-5010 - (NORSE EIGHT) — Outlook Therapeutics Inc. — Regulatory Decision
- 2026-06-17: AMT-130 — uniQure N.V. — Submission
- 2026-06-17: Ketamir-2 — MIRA Pharmaceuticals Inc. — Phase 2
- 2026-06-17: PER-001 — Bayer AG ADR — Phase 2
- 2026-06-17: Utebzi (Tebipenem HBr) - (PIVOT-PO) — GSK plc American Depositary Shares (Each representing two) — Approved
- 2026-06-17: Cell Pouch Bio-hybrid Organ — Eledon Pharmaceuticals Inc. — Phase 1/2
- 2026-06-17: Relacorilant - (GRACE) — Corcept Therapeutics Incorporated — Submission
- 2026-06-17: ELI-002 - (AMPLIFY-7P) — Elicio Therapeutics Inc. — Phase 2
- 2026-06-17: NEO212 — NeOnc Technologies Holdings Inc. — IND-Enabling
- 2026-06-17: Alixorexton (ALKS 2680) - (Vibrance-2) — Alkermes plc — Phase 2
- 2026-06-17: AXPAXLI (OTX-TKI) - (SOL-R) — Ocular Therapeutix Inc. — Submission
- 2026-06-17: PER-001 — Bayer AG ADR — Phase 1/2
- 2026-06-17: LX2006 - (SUNRISE-FA) — Lexeo Therapeutics, Inc. — Topline Data
- 2026-06-17: VS-6766 and defactinib - (RAMP 205) — Verastem Inc. — Phase 1/2
- 2026-06-18: Lunsumio (mosunetuzumab) - (SUNMO) — Roche Holding AG ADR — Regulatory Decision
- 2026-06-18: Optune (EF-32) - (TRIDENT) — NovoCure Limited — End of Phase Meeting
- 2026-06-18: GRI-0621-IPF-02 — GRI Bio Inc. — Phase 2
- 2026-06-18: Ateganosine (THIO-101) — MAIA Biotechnology Inc. — Phase 2
- 2026-06-18: mRNA-1010 - (P304) — Moderna Inc. — Regulatory Decision
- 2026-06-18: Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC) — AIM ImmunoTech Inc. — Topline Data
- 2026-06-18: CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) - (STRIDE-13) — Merck & Company Inc. — Approved
- 2026-06-18: KIO-300 — Kiora Pharmaceuticals Inc. — Conference Presentation
- 2026-06-19: Ecopipam - (D1AMOND) — Teva Pharmaceutical Industries Limited American Depositary Shares — Submission
- 2026-06-19: AMT-260 - (GenTLE) — uniQure N.V. — Conference Presentation
- 2026-06-20: Cytisinicline - (ORCA-3) — Achieve Life Sciences Inc. — Regulatory Decision
- 2026-06-22: ML-004 - (IRIS) — MapLight Therapeutics Inc. — End of Phase Meeting
- 2026-06-22: Elsunersen (PRAX-222) - (EMBRAVE) — Invitae Corporation — Topline Data
- 2026-06-22: PM359 — Prime Medicine Inc. — Initial Data
- 2026-06-22: C5 Combo (pozelimab and cemdisiran) - (NIMBLE) — Regeneron Pharmaceuticals Inc. — Regulatory Decision
- 2026-06-22: Tegoprubart (AT-1501) - (BESTOW) — Eledon Pharmaceuticals Inc. — Conference Presentation
- 2026-06-22: DT120 ODT (Lysergide (LSD)) - (Emerge) — Definium Therapeutics Inc. — Submission
- 2026-06-22: QTORIN rapamycin - (SELVA) — Palvella Therapeutics Inc. — Submission
- 2026-06-22: NRX-101 — NRX Pharmaceuticals Inc. — Initial Data
- 2026-06-22: Tulisokibart (MK-7240) - (ATLAS-UC) — Merck & Company Inc. — Topline Data
- 2026-06-22: TSC-100, TSC-101 - (ALLOHA) — TScan Therapeutics Inc. — Phase 1
- 2026-06-22: SigVie-002 (Be6A Lung-01) — Pfizer Inc. — Topline Data
- 2026-06-22: TSHA-102 - (REVEAL) — Taysha Gene Therapies Inc. — Topline Data
- 2026-06-22: Nanobody (sonelokimab) - (VELA-2) — MoonLake Immunotherapeutics — Regulatory Decision
- 2026-06-22: Nanobody (sonelokimab) - (VELA-1) — MoonLake Immunotherapeutics — Regulatory Decision
- 2026-06-22: Cytisinicline - (ORCA-3) — Achieve Life Sciences Inc. — Regulatory Decision
- 2026-06-22: Nanobody (sonelokimab) - (VELA-TEEN) — MoonLake Immunotherapeutics — Regulatory Decision
- 2026-06-22: YCANTH (cantharidin, VP-102) - (COVE-3) — Verrica Pharmaceuticals Inc. — Phase 3
- 2026-06-22: CMND-100 — Clearmind Medicine Inc. — Phase 1/2
- 2026-06-22: Tegoprubart (AT-1501) - (BESTOW) — Eledon Pharmaceuticals Inc. — Interim Data
- 2026-06-23: Arimoclomol (EAP) - (NPC002) — Zevra Therapeutics Inc. — Phase 3
- 2026-06-23: Zasocitinib (TAK-279) - (LATITUDE PsO) — Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) — Topline Data
- 2026-06-23: IMNN-001 - (OVATION 3) — Imunon Inc. — Submission
- 2026-06-23: VOQUEZNA (vonoprazan) - (pHalcon-EoE-201) — Phathom Pharmaceuticals Inc. — Topline Data
- 2026-06-23: DM199 (rinvecalinase alfa) — DiaMedica Therapeutics Inc. — Phase 2
- 2026-06-23: QRX003 - (CL-QRX003-002) — Quoin Pharmaceuticals Ltd. — Submission
- 2026-06-23: EB613 — Entera Bio Ltd. — Conference Presentation
- 2026-06-23: Daraxonrasib - (RASolute 305) — Revolution Medicines Inc - Ordinary Shares — Phase 3
- 2026-06-23: GR-MD-02 (belapectin) - (NAVIGATE) — Galectin Therapeutics Inc. — End of Phase Meeting
- 2026-06-23: VS-7375 - (TARGET-D 101) — Verastem Inc. — End of Phase Meeting
- 2026-06-23: XL092 with atezolizumab - (STELLAR-303) — Exelixis Inc. — Regulatory Decision
- 2026-06-23: AMX0114 - (LUMINA) — Amylyx Pharmaceuticals Inc. — End of Phase Meeting
- 2026-06-23: VS-7375 - (TARGET-D 101) — Verastem Inc. — Initial Data
- 2026-06-24: Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) - (ASCENT-04/KEYNOTE-D19) — Gilead Sciences Inc. — Submission
- 2026-06-24: TRYNGOLZA (olezarsen) - (CORE) — Ionis Pharmaceuticals Inc. — Approved
- 2026-06-24: IBRANCE (palbociclib) in combination with trastuzumab, with or without pertuzumab - (PATINA) — Pfizer Inc. — Conference Presentation
- 2026-06-24: NHBE GalNAc siRNA (WVE-007) - (INLIGHT) — Wave Life Sciences Ltd. — Phase 2a
- 2026-06-24: VK3019 — Viking Therapeutics Inc. — Phase 1
- 2026-06-24: ABS-201 - (HEADLINE) — Absci Corporation — Interim Data
- 2026-06-24: Zervimesine (CT1812) - (SHIMMER) — Cognition Therapeutics Inc. — End of Phase Meeting
- 2026-06-24: RGX-202 - (AFFINITY DUCHENNE) — REGENXBIO Inc. — Topline Data
- 2026-06-24: Auxora - (KOURAGE) — CalciMedica Inc. — Interim Data
- 2026-06-24: CLD-401 — Calidi Biotherapeutics Inc. — Preclinical
- 2026-06-24: HLP003 (previously CYB003) - (APPROACH) — Cybin Inc. — Topline Data
- 2026-06-24: COYA 302 - (ALSTARS) — Coya Therapeutics Inc. — Conference Presentation
- 2026-06-24: ELI-002 - (AMPLIFY-7P) — Elicio Therapeutics Inc. — Conference Presentation
- 2026-06-25: Bemnifosbuvir and ruzasvir (RZR) - (C-FORWARD) — Atea Pharmaceuticals Inc. — Topline Data
- 2026-06-25: fanregratinib - (HMPL-453) — HUTCHMED (China) Limited — Conference Presentation
- 2026-06-25: KT-621 - (BroADen2) — Kymera Therapeutics Inc. — Topline Data
- 2026-06-25: Tegoprubart (AT-1501) - (BESTOW) — Eledon Pharmaceuticals Inc. — Phase 3
- 2026-06-25: AX-0810 — ProQR Therapeutics N.V. — Submission
- 2026-06-25: TSHA-102 - (REVEAL) — Taysha Gene Therapies Inc. — End of Phase Meeting
- 2026-06-25: PrimeC - (RoAD) — NeuroSense Therapeutics Ltd. — Phase 2
- 2026-06-26: Lumvoa (veligrotug-vvze) - (THRIVE) — Viridian Therapeutics Inc. — Regulatory Decision
- 2026-06-26: LNTH-2501 (Gallium-68 edotreotide) — Lantheus Holdings Inc. — Regulatory Decision
- 2026-06-26: SKYRIZI (risankizumab-rzaa) — AbbVie Inc. — Approved
- 2026-06-26: HMB-002 - (VELORA Discover) — Hemab Therapeutics Holdings Inc. — Conference Presentation
- 2026-06-26: Sunosi (Solriamfetol) - (FOCUS-3) — Axsome Therapeutics Inc. — Phase 3
- 2026-06-26: GH1001 (GH001-PPD-203) — GH Research PLC — Phase 2a
- 2026-06-29: Nefecon (VR-205) — Calliditas Therapeutics AB — Submission
- 2026-06-29: Lumvoa (veligrotug-vvze) - (THRIVE-2) — Viridian Therapeutics Inc. — Submission
- 2026-06-29: GT-02287 — Gain Therapeutics Inc. — Phase 2
- 2026-06-29: ALN1003 — Alaunos Therapeutics Inc. — Preclinical
- 2026-06-29: BHV-1300 — Biohaven Ltd. — Phase 3
- 2026-06-29: Epcoritamab (Epcor) Plus Lenalidomide - (EPCORE DLBCL-4) — AbbVie Inc. — End of Phase Meeting
- 2026-06-29: TDP-43 (PARADIGM) — NeuroSense Therapeutics Ltd. — Phase 2b
- 2026-06-29: EVO756 — Evommune Inc. — Phase 2b
- 2026-06-29: Claseprubart (DNTH103) - (EMERGE) — Dianthus Therapeutics Inc. — Conference Presentation
- 2026-06-29: ART26.12 — Artelo Biosciences Inc. — Initial Data
- 2026-06-29: NV-387 — NanoViricides Inc. — Phase 1
- 2026-06-29: 4D-150 - (4FRONT-2) — 4D Molecular Therapeutics Inc. — Topline Data
- 2026-06-29: TSHA-102 - (REVEAL) — Taysha Gene Therapies Inc. — Conference Presentation
- 2026-06-29: Infigratinib - (ACCEL) — BridgeBio Pharma Inc. — Conference Presentation
- 2026-06-29: Low-dose infigratinib - (PROPEL3) — BridgeBio Pharma Inc. — Conference Presentation
- 2026-06-29: ZORYVE (roflumilast) Cream 0.3% — Arcutis Biotherapeutics Inc. — Regulatory Decision
- 2026-06-29: Oxylanthanum Carbonate (OLC) — Unicycive Therapeutics Inc. — Regulatory Decision
- 2026-06-29: LNTH-2501 (Gallium-68 edotreotide) — Lantheus Holdings Inc. — Regulatory Decision
- 2026-06-30: Zorevunersen (STK-001) - (EMPEROR) — Stoke Therapeutics Inc. — Submission
- 2026-06-30: PT00114 — Protagenic Therapeutics Inc. — Topline Data
- 2026-06-30: PH94B - (PALISADE-4) — Vistagen Therapeutics Inc. — Topline Data
- 2026-06-30: Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE) — Moleculin Biotech Inc. — Interim Data
- 2026-06-30: Opakalim (BHV-7000) - (RISE-3) — Biohaven Ltd. — Phase 2/3
- 2026-06-30: Surabgene lomparvovec (sura-vec, ABBV-RGX-314) - (NAAVIGATE) — AbbVie Inc. — End of Phase Meeting
- 2026-06-30: BRUKINSA (zanubrutinib) plus rituximab - (MANGROVE) — BeOne Medicines Ltd. — Submission
- 2026-06-30: ACI-24 (anti-Abeta vaccine) - (ABATE) — AC Immune SA — Interim Data
- 2026-06-30: Olvimulogene Nanivacirepvec (Olvi-Vec) (OnPrime/GOG-3076) - (VIRO-15) — Genelux Corporation — Phase 1/2
- 2026-06-30: Vafseo (vadadustat)(TIW) versus an erythropoiesis-stimulating agent (ESA). - (VOICE) — Akebia Therapeutics Inc. — End of Phase Meeting
- 2026-06-30: ALXN1840 (WTX101) - (FoCus) — AstraZeneca PLC — Submission
- 2026-06-30: ZORYVE (roflumilast) Cream 0.3% — Arcutis Biotherapeutics Inc. — Approved
- 2026-06-30: AGAMREE (vamorolone) — Catalyst Pharmaceuticals Inc. — Topline Data
- 2026-06-30: DT-818 — Design Therapeutics Inc. — Phase 1
- 2026-06-30: OST-HER2 (AOST-2121) — OS Therapies Incorporated — Submission
- 2026-06-30: TransCon CNP (navepegritide) - (ApproaCH) — Ascendis Pharma A/S — Conference Presentation
- 2026-06-30: PIPE-791 — Contineum Therapeutics Inc. — Phase 1
- 2026-06-30: AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) — Sarepta Therapeutics Inc. — Regulatory Decision
- 2026-06-30: SCY-770 (PXL-770) — SCYNEXIS Inc. — Topline Data
- 2026-06-30: ZYNLONTA (Loncastuximab Tesirine-Ipyl) - (LOTIS-7) — ADC Therapeutics SA — Submission
- 2026-06-30: PAS-004 — Pasithea Therapeutics Corp. — Interim Data
- 2026-06-30: Oxylanthanum Carbonate (OLC) — Unicycive Therapeutics Inc. — Submission
- 2026-06-30: DM199 (rinvecalinase alfa) — DiaMedica Therapeutics Inc. — Phase 2
- 2026-06-30: VS-7375 -(TARGET-D 203) — Verastem Inc. — Interim Data
- 2026-06-30: Seralutinib (GB002) - (TORREY/PROSERA) — Gossamer Bio Inc. — End of Phase Meeting
- 2026-06-30: Resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) - (RESET-PV) — Cabaletta Bio Inc. — Interim Data
- 2026-06-30: Nanobody (sonelokimab) - (VELA-1) — MoonLake Immunotherapeutics — Interim Data
- 2026-06-30: Zervimesine (CT1812) - (SHIMMER) — Cognition Therapeutics Inc. — End of Phase Meeting
- 2026-06-30: ARGX-213 - (FcRn) — argenx SE — Initial Data
- 2026-06-30: Olezarsen - (CORE) — Ionis Pharmaceuticals Inc. — Regulatory Decision
- 2026-06-30: DM199 (rinvecalinase alfa) — DiaMedica Therapeutics Inc. — Initial Data
- 2026-06-30: Imfinzi (durvalumab) - (NILE) — AstraZeneca PLC — Interim Data
- 2026-06-30: GFH375/VS-7375 — Verastem Inc. — Interim Data
- 2026-06-30: Sovleplenib - (ESLIM-02) — HUTCHMED (China) Limited — Submission
- 2026-06-30: CTIM-76 — Context Therapeutics Inc. — Interim Data
- 2026-06-30: Delpacibart braxlosiran (del-brax) - (FORTITUDE) — Atrium Therapeutics Inc. — Submission
- 2026-06-30: Veligrotug (VRDN-001) - (THRIVE-2) — Viridian Therapeutics Inc. — Regulatory Decision
- 2026-06-30: Votoplam - (PIVOT-HD) — Novartis AG — Full Results
- 2026-06-30: Prulacabtagene leucel (prula-cel, formerly ADI-001) — Adicet Bio Inc. — Initial Data
- 2026-06-30: Azenosertib (ZN-c3) - (TETON) — Zentalis Pharmaceuticals Inc. — Interim Data
- 2026-06-30: TSC-100, TSC-101 - (ALLOHA) — TScan Therapeutics Inc. — Initial Data
- 2026-06-30: Aglatimagene besadenovec (CAN-2409) - (ULYSSES) — Candel Therapeutics Inc. — Interim Data
- 2026-06-30: AN2-502998 — AN2 Therapeutics Inc. — Interim Data
- 2026-06-30: Viaskin Peanut - (VITESSE) — DBV Technologies S.A. — Submission
- 2026-06-30: TRIKAFTA — Vertex Pharmaceuticals Incorporated — Submission
- 2026-06-30: MP0533 — Molecular Partners AG — Interim Data
- 2026-06-30: Elraglusib in Combination with FOLFIRINOX and Losartan — Actuate Therapeutics Inc. — Initial Data
- 2026-06-30: Vanoglipel (DA-1241) — MetaVia Inc. — End of Phase Meeting
- 2026-06-30: LB-100 with doxorubicin — Lixte Biotechnology Holdings Inc. — Initial Data
- 2026-06-30: ABS-201 - (HEADLINE) — Absci Corporation — Interim Data
- 2026-06-30: Otoferlin gene therapy (DB-OTO) - (CHORD) — Regeneron Pharmaceuticals Inc. — Regulatory Decision
- 2026-06-30: GLPG3667 - (GALACELA) — Lakefront Biotherapeutics Sponsored ADR — Topline Data
- 2026-06-30: Prulacabtagene leucel (prula-cel, formerly ADI-001) — Adicet Bio Inc. — Interim Data
- 2026-06-30: Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1) — Puma Biotechnology Inc — Interim Data
- 2026-06-30: TBS-2025 - (VISTA) — TuHURA Biosciences Inc. — End of Phase Meeting
- 2026-06-30: ACI-24 (anti-Abeta vaccine) — AC Immune SA — Interim Data
- 2026-06-30: AX-0810 — ProQR Therapeutics N.V. — Interim Data
- 2026-06-30: QTORIN pitavastatin — Palvella Therapeutics Inc. — Submission
- 2026-06-30: VRDN-001 - (THRIVE) — Viridian Therapeutics Inc. — Regulatory Decision
- 2026-06-30: EDG-15400 — Edgewise Therapeutics Inc. — Initial Data
- 2026-06-30: Sovleplenib - (China trial) — HUTCHMED (China) Limited — Submission
- 2026-06-30: Neldaleucel (MT-601) - (APOLLO) — Marker Therapeutics Inc. — Interim Data
- 2026-06-30: TransCon IL-2 β/γ - (IL-βelieγe) — Ascendis Pharma A/S — Interim Data
- 2026-06-30: ALLO-329 - (RESOLUTION) — Allogene Therapeutics Inc. — Initial Data
- 2026-06-30: FT819-102 — Fate Therapeutics Inc. — Conference Presentation
- 2026-06-30: SGR-3515 (Wee1 inhibitor) — Schrodinger Inc. — Topline Data
- 2026-06-30: Nomlabofusp (CTI-1601) — Larimar Therapeutics Inc. — Submission
- 2026-06-30: BMF-650 (GLP-131) — Biomea Fusion Inc. — Initial Data
- 2026-06-30: REC-1245 - (DAHLIA) — Recursion Pharmaceuticals Inc. — Initial Data
- 2026-06-30: Pelacarsen (TQJ230) (AKCEA-APO(a)-LRx) — Ionis Pharmaceuticals Inc. — Initial Data
- 2026-06-30: Orforglipron - (ACHIEVE-4) — Eli Lilly and Company — Submission
- 2026-06-30: C5 Combo (pozelimab and cemdisiran) - (NIMBLE) — Regeneron Pharmaceuticals Inc. — Submission
- 2026-06-30: AQST-108 (epinephrine) Topical Gel — Aquestive Therapeutics Inc. — Topline Data
- 2026-06-30: StealthX - (Project NextGen, NIAID trial) — Capricor Therapeutics Inc. — Initial Data
- 2026-06-30: EVO756 — Evommune Inc. — Initial Data
- 2026-06-30: BA3182 — BioAtla Inc. — Full Results
- 2026-06-30: WAKIX - (Pitolisant GR) — Harmony Biosciences Holdings Inc. — Submission
- 2026-06-30: Datopotamab deruxtecan - (TROPION-PanTumor01) — AstraZeneca PLC — Interim Data
- 2026-06-30: NCEL-101 + tegoprubart (AT-1501) — Eledon Pharmaceuticals Inc. — Submission
- 2026-06-30: Tebipenem pivoxil — GSK plc American Depositary Shares (Each representing two) — Regulatory Decision
- 2026-06-30: Phentolamine ophthalmic solution - (LYNX-3) — Opus Genetics Inc. — Topline Data
- 2026-06-30: BHV-7000 — Biohaven Ltd. — Regulatory Decision
- 2026-06-30: Nanobody (sonelokimab) - (VELA-2) — MoonLake Immunotherapeutics — Interim Data
- 2026-06-30: TTI-109 — Tvardi Therapeutics Inc. — Topline Data
- 2026-06-30: ARGX-119 — argenx SE — Topline Data
- 2026-06-30: BMN 401 (INZ-701) - (ENERGY-3) — BioMarin Pharmaceutical Inc. — Topline Data
- 2026-06-30: Sogroya (somapacitan) - (REAL8) — Novo Nordisk A/S — Regulatory Decision
- 2026-06-30: Atacicept - (PIONEER) — Vera Therapeutics Inc. — Initial Data
- 2026-06-30: JADE-001 — Jade Biosciences Inc. — Interim Data
- 2026-06-30: SGR-3515 — Schrodinger Inc. — Initial Data
- 2026-06-30: ACI-24 (anti-Abeta vaccine) - (ABATE) — AC Immune SA — Interim Data
- 2026-06-30: Tyvaso (treprostinil) - (TETON PPF) — United Therapeutics Corporation — Topline Data
- 2026-06-30: ENHERTU (trastuzumab deruxtecan) - (DESTINY-Lung04) — AstraZeneca PLC — Topline Data
- 2026-06-30: OST-504 (ADXS-504) — OS Therapies Incorporated — Interim Data
- 2026-06-30: Civaparvovec (ST-920) - (STAAR) — Sangamo Therapeutics Inc. — Submission
- 2026-06-30: Bremelanotide + PDE5i — Palatin Technologies Inc. — Topline Data
- 2026-06-30: TERN-701 - (CARDINAL) — Merck & Company Inc. — Full Results
- 2026-06-30: BT7480 with nivolumab — Bicycle Therapeutics plc — Interim Data
- 2026-06-30: PUMA-ALI-1201 - (ALISCA-Breast1) — Puma Biotechnology Inc — Interim Data
- 2026-06-30: DT120 ODT (Lysergide (LSD)) - (Emerge) — Definium Therapeutics Inc. — Topline Data
- 2026-06-30: PH94B - (PALISADE-4) — Vistagen Therapeutics Inc. — Topline Data
- 2026-06-30: VOXZOGO — BioMarin Pharmaceutical Inc. — Topline Data
- 2026-06-30: cretostimogene - (PIVOT-006) (EAP) — CG Oncology, Inc. — Topline Data
- 2026-06-30: TYVASO (treprostinil) - (TETON) — United Therapeutics Corporation — Phase 3
- 2026-06-30: AMT-162 — uniQure N.V. — Initial Data
- 2026-06-30: Zelenectide pevedotin (BT8009) - (Duravelo-1) — BioAtla Inc. — Full Results
- 2026-06-30: LYL273 (GCC19CART) — Lyell Immunopharma Inc. — Submission
- 2026-06-30: PAS-004 — Pasithea Therapeutics Corp. — Interim Data
- 2026-06-30: Miv-cel (mivocabtagene autoleucel, KYV-101) - (KYSA-8) — Kyverna Therapeutics Inc. — Submission
FDA Events Calendar
June 2026
Sun
Mon
Tue
Wed
Thu
Fri
Sat
1
2
6
8
12
14
21
24
27
28
Clinical Read
Regulatory
Meetings & Presentations